| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.062 | 0.3 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | BRD-K79669418 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.3 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.057 | 0.3 |
| mRNA | GW-405833 | CTRPv2 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |